Alterity’s ATH434 Advances in Phase 2 MSA Trial

Alterity Therapeutics (ATHE) has released an update.

Alterity Therapeutics has announced that its Phase 2 clinical trial of ATH434 for early-stage multiple system atrophy (MSA) will continue as recommended by the independent Data Monitoring Committee, which found no safety concerns. The trial is expected to be completed by November 2024, with top-line data anticipated in January 2025. ATH434 is an oral agent aimed at inhibiting the aggregation of neurodegenerative proteins and has already shown promise in Phase 1 studies.

For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.